TAKEDA CALIFORNIA, INC
San Diego, United States
Holger Monenschein received his PhD from the Technical University of Clausthal-Zellerfeld, Germany. Afterwards, he moved to San Diego to conduct post doctoral studies in the group of Prof. K.C. Nicolaou at The Scripps Research Institute, working on the total synthesis of complex natural products. Holger started his industry career at Amgen, Inc. as a medicinal chemist, and quickly became an integral part of the medicinal chemistry department, focusing mainly on diseases of the central nervous system such as Alzheimer's disease and pain. In 2010, Holger moved to Jupiter, Florida where he initiated medicinal chemistry research and discovery at the small biotech startup Envoy Therapeutics. At Envoy, Holger drove the internal drug discovery pipeline from early HTS to the identification of clinical candidates and managed a strong network of supporting CROs to deliver key project data in the fields of in vivo pharmacology, DMPK, and toxicology. In 2013, Holger moved to Takeda California as part of Takeda's acquisition of Envoy. At Takeda he is now director of medicinal chemistry operations in the field of CNS and early target validation.